Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 2

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2

Conditions

Multiple Myeloma 70Leukemia, Lymphocytic, Chronic, B-Cell 26Lymphoma, Mantle-Cell 15Lymphoma, Follicular 15Lymphoma, Large B-Cell, Diffuse 14Leukemia, Myeloid, Acute 14Lymphoma, B-Cell, Marginal Zone 13Lymphoma, Non-Hodgkin 12Recurrence 11Neoplasms, Plasma Cell 10Lymphoma 10Myelodysplastic Syndromes 9Hodgkin Disease 8Neoplasms 7Leukemia 7Burkitt Lymphoma 7Waldenstrom Macroglobulinemia 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, T-Cell, Cutaneous 6Lymphoma, B-Cell 6Sezary Syndrome 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Mycosis Fungoides 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Large-Cell, Immunoblastic 4Astrocytoma 4Smoldering Multiple Myeloma 3Prostatic Neoplasms 3Oligodendroglioma 3Melanoma 3

Interventions

Bortezomib 3filanesib 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Lenalidomide 2Dexamethasone 2sargramostim 1montanide ISA 51 1merphos 1liposomal doxorubicin 1ixazomib 1itacitinib 1incomplete Freund's adjuvant 1fludarabine phosphate 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1auricularum 1Steroids 1Stem Cell Transplantation 1Sirolimus 1Proteasome Inhibitors 1Methotrexate 1Injections, Subcutaneous 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Plasma Cell × Lenalidomide × Clear all
NCT02334865 2026-05-15

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Roswell Park Cancer Institute

Phase 1 Active not recruiting
18 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

NCT03591744 2018-12-19

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

City of Hope Medical Center

Phase 1 Withdrawn
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡